Business
Queens University Belfast funding
Queens University Belfast funding.
About this update from Fusion Antibodies Plc
[{"type":"text","content":"\n \n \n RNS Number : 7842V\n Fusion Antibodies PLC\n 11 August 2020\n \n \n \n \n Fusion Antibodies plc\n \n \n (\"Fusion\" or the \"Company\")\n \n \n Queens University Belfast funding\n \n \n Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, notes the press release issued today from Queens University Belfast (\"QUB\"). QUB has been awarded up to £50k of funding \n to develop new initiatives to enhance life science research and development in Northern Ireland. As a partner of QUB, Fusion can maximise this opportunity through increased research, innovation and productivity. \n \n \n Fusion and QUB have not agreed to any financial arrangements in respect of the grant to QUB, and the arrangement is not expected to materially impact Fusion's revenue or working capital position.\n \n \n \n Dr. Paul Kerr CEO of Fusion Antibodies commented:\n \n \n \"We welcome and support the invitation to what we consider to be one of the UK's leading R&D funding programmes. This will further strengthen our existing relationship with QUB and we look forward to expanding on our collaborations with them. The potential to access grant funding via the\n \n Northern Ireland Precision Biomarkers and Therapeutics Consortium (NIPBT) is very exciting for us and the health & life sciences sector in Northern Ireland as a whole.\"\n \n \n \n The full press release from QUB can be viewed below. \n \n Enquiries:\n \n \n \n \n Fusion Antibodies plc\n \n \n \n www.fusionantibodies.com\n \n \n \n \n \n Dr Paul Kerr, Chief Executive Officer\n \n \n Via Walbrook PR\n \n \n \n \n James Fair, Chief Financial Officer\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Allenby Capital Limited\n \n \n Tel: +44 (0)20 3328 5656 \n \n \n \n \n James Reeve / Asha Chotai (Corporate Finance)\n \n \n \n \n \n \n \n Tony Quirke (Sales)\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Walbrook PR\n \n \n Tel: +44 (0)20 7933 8780 or [email protected]\n \n \n \n \n Anna Dunphy\n \n \n Mob: +44 (0)7876 741 001\n \n \n \n \n Paul McManus\n \n \n Mob: +44 (0)7980 541 893\n \n \n \n \n \n \n \n \n \n About Fusion Antibodies plc\n \n Fusion is a Belfast based contract research ...